Top 10 Fastest-Growing Medical Device Products

EY estimates that the global medical device market will register a growth rate of approximately 6% for the full year of 2025, with the overall market maintaining steady growth. As some sectors lose their growth dynamism, which new tracks are emerging to become the new driving forces for industry growth?

By sorting out the performance of major global medical device players, we have selected ten large single-product tracks with growth rates far exceeding the industry average. These tracks have a year-on-year market size growth rate of over 15%. Industry leaders focusing on these tracks have achieved rapid growth through innovative products and their performance has far surpassed that of peers.

Pulsed field ablation in cardiac electrophysiology has achieved an unparalleled growth rate. As an innovative product, PFA has achieved a penetration rate of over 20% in the US electrophysiology market and a market size of over 2 billion US dollars in less than two years after its approval. Investors believe it is expected to become the track with the fastest revenue growth and market scale expansion in history both domestically and internationally.

The rapid penetration of PFA is first attributed to its outstanding clinical value. Different from radiofrequency ablation and cryoablation, pulsed field ablation has high tissue selectivity, which can effectively ablate diseased myocardial cells while minimizing damage to adjacent important structures such as the esophagus, phrenic nerve and coronary artery. The preliminary ablation effect is clear, and studies show that its immediate success rate of pulmonary vein isolation reaches 98% - 100%. The 1-year follow-up results of multiple studies indicate that its single-procedure success rate for paroxysmal atrial fibrillation is 70% - 80%, which is not inferior to traditional temperature ablation, and it shows better long-term effects in some studies. It can also shorten the operation time and improve surgical efficiency.

In terms of commercialization, the joint layout and vigorous promotion by industry giants have boosted the rapid penetration of PFA. Boston Scientific and Medtronic are the current global leaders in the PFA market, and the two cardiovascular giants have invested a lot of resources to promote the commercialization of PFA. The global surgical volume of Boston Scientific's Farapulse PFA system has exceeded 500,000 cases. In fiscal year 2025, Medtronic's PFA ablation revenue was about 1 billion US dollars, and it is expected to increase by another 1 billion US dollars in 2026. At the same time, the subsequent layout of PFA by Johnson & Johnson and Abbott, the two "kings" of radiofrequency ablation in cardiac electrophysiology, also provides continuous endorsement for this track.

PFA is still far from reaching the market ceiling. In its speech at the JPM Conference at the beginning of 2026, Medtronic positioned PFA as a track with a scale of more than 13 billion US dollars and an annual growth rate of over 25%, and it is expected that the penetration rate of PFA will rise to 80% by 2028. Building a complete ecosystem, enriching supporting mapping systems and catheter types, and linking with other cardiovascular interventional businesses have become the strategic consensus of major participants.

Looking at the domestic PFA market, it is currently in the introduction period. More than 5 domestic products have been approved, driving the rapid growth of clinical application volume. Domestic products also have a fast iteration speed, and have taken the lead in laying out a number of innovative technologies in the PFA field. It is expected that after industrial integration in the future, with the gradual improvement of product supporting facilities, continuous optimization of stability and improvement of image accuracy, domestic cardiac electrophysiology enterprises are expected to rise with PFA technology.

From the perspective of clinical value, disposable endoscopes solve the problem of cross-infection of reusable endoscopes and greatly reduce the hospital's purchase cost and disinfection cost. In recent years, the penetration rate of disposable endoscopes has increased rapidly worldwide, and after achieving a high penetration rate in urology, it has quickly expanded to multiple departments.

From the perspective of industrial transformation, disposable endoscopes are products bred by scientific and technological revolution and industrial innovation. The rapid development of CMOS image sensor chip technology, the independent and controllable domestic chips, and large-scale, automated production have greatly reduced the cost of disposable endoscopes, laying the foundation for their application in multiple departments.

The performance of global leaders has sent a clear signal of sustained growth. Ambu, a global pioneer in disposable endoscopes, achieved a year-on-year revenue growth of over 25% in disposable endoscopes in urology, otolaryngology, and gastrointestinal departments in the first three quarters of 2025, and the overall momentum remains strong even if the growth rate in the respiratory field slows down. CEO Britt Meelby Jensen expects the market to maintain a compound annual growth rate of over 20% in the future. Enterprises are not only following demand, but also taking the initiative to promote the migration of departmental usage habits. In the future, Ambu will focus on urology and respiratory systems, followed by otolaryngology, and gradually guide the use of endoscopes in these departments from reusable to disposable.

The disposable endoscope market still has broad space. The global endoscope market has an annual growth rate of about 5%, but disposable endoscopes have maintained a growth rate of over 20% for two consecutive years. With the continuous rise in demand for aging, chronic diseases and minimally invasive surgery, hospitals' reliance on safe, efficient and low-cost solutions will be further enhanced. In the future, as disposable endoscopes further gain advantages in image clarity, comparable to traditional endoscopes, they are even expected to realize substitution in the field of gastroenteroscopes.

Relying on supply chain advantages and rapid response capabilities, domestic enterprises have become the core global supply force, cooperating with giants such as Olympus, Cook and Hologic to go overseas, and are pushing Made in China to the global stage. After disposable ureteroscopes are included in the national centralized procurement in 2026, the sharp drop in prices will further drive the leap in domestic penetration rate, forming a two-way acceleration of demand explosion and cost reduction.

Since the advent of laparoscopic surgical robots 20 years ago, even though their penetration rate in global minimally invasive surgery is less than 15%, the market size has exceeded 10 billion US dollars with an average annual growth rate of over 20%. Their life cycle has surpassed that of general innovative medical device products.

The core reason why laparoscopic surgical robots can achieve long-term development is their widely recognized clinical value. The clinical value of laparoscopic surgical robots spans multiple departments, mainly used in critical tumor surgeries, which greatly reduces the difficulty of laparoscopic surgery. A laparoscopic surgical robot usually consists of a doctor's console, a patient surgery platform and an imaging system. Surgeons remotely control the surgical instruments connected to the robotic arm through the patient surgery platform to complete surgical steps such as compression, cutting, hemostasis, dissection, suturing and tissue manipulation, which is more accurate than manual operation and easier to complete surgery in a narrow space.

New products of Intuitive Surgical have also injected a steady stream of growth momentum into the market. The global laparoscopic surgical robot market is dominated by Intuitive Surgical with its da Vinci surgical robot. The da Vinci surgical robot has undergone five innovations in the more than 20 years since its advent, and each innovation has achieved a leap in image display, supporting of advanced surgical instruments and operability. The latest generation da Vinci 5 (approved by the FDA in 2024) has powerful computing capabilities and force feedback functions. The cumulative installed capacity of this new product has reached 1,232 units in two years, including 870 units installed in 2025 and 362 units installed in 2024. Sustained innovation has led to sustained market growth.

Sustained innovation capabilities have also brought substantial financial returns. In 2025, Intuitive Surgical, the parent company of the da Vinci surgical system, achieved a revenue of over 10 billion US dollars, a year-on-year increase of 21%; the year-on-year growth rate of the surgical volume of the da Vinci surgical robot is expected to be 13% to 15% in 2025. In the whole year of 2025, a total of 1,721 da Vinci surgical systems were installed, with a total installed capacity higher than the 1,526 units in 2024.

The competition in the surgical robot market will become more fierce in 2026. At the 2026 JPM Conference, both Johnson & Johnson and Medtronic mentioned that laparoscopic surgical robots are key promotion projects. The differentiated competitive point between the two giants and the da Vinci surgical robot is the integration of surgical robots with advanced surgical instruments for minimally invasive surgery.

The domestic surgical robot market has also ushered in a growth window. According to the data of Zhongcheng Shuke, the sales volume of domestic laparoscopic surgical robots from January to November 2025 reached 119 units. At the same time, domestic laparoscopic surgical robots achieved higher-than-expected growth in the overseas market in 2025. After domestic laparoscopic surgical robots open channels and build brands in emerging markets, they are expected to maintain sustained growth. In 2026, the domestic configuration certification for large medical devices is expected to be further liberalized, which will drive the expansion of the domestic laparoscopic surgical robot market size.

Laparoscopic surgical robots have established the "heavyweight innovation" of medical technology with a huge and sophisticated engineering system, while CGM has proven with its tiny and exquisite size that a coin-sized product can also open up a rapidly growing billion-dollar market.

CGM solves the persistent problem in the chronic disease management market, and addresses the difficulties of diabetes patients in chronic disease management through innovations in biosensor and algorithm technologies. CGM is a technology that continuously monitors the glucose concentration in the interstitial fluid of subcutaneous tissue through a glucose sensor, which can indirectly reflect the blood glucose level and provide continuous and comprehensive 24-hour blood glucose information. It has evolved from blood glucose testing by pricking fingers to non-sensing all-day blood glucose monitoring.

From the perspective of industrial promotion, the rapid coverage of US medical insurance has driven the rapid volume expansion of CGM. The global CGM market is dominated by two enterprises: Abbott and Dexcom. US medical insurance included CGM in its coverage as early as 2017 and has continuously expanded the coverage, greatly reducing the economic burden on patients for adopting innovative products. Abbott's CGM product sales are expected to break through 8 billion US dollars in 2025, a year-on-year increase of about 23%. Dexcom expects its revenue to reach 4.63-4.65 billion US dollars in 2025, a year-on-year increase of about 15%.

The CGM market still has great room for incremental growth. Abbott believes that the current penetration rate of CGM in the US is about 20% and about 5% worldwide, and it is expected that the CGM market will further grow in 2026.

Although CGM has not been included in medical insurance in China, relying on the cost advantages of local enterprises in the supply chain and manufacturing end, CGM has successfully opened the self-paid market. The performance of industry leaders is particularly outstanding: Weitech Medical's CGM revenue reached 143 million yuan in the first half of 2025, a year-on-year surge of 91.5%; Yuyue Medical also publicly stated that its CGM business maintains significant growth and its market share continues to climb. It can be seen that driven by both cost reduction and demand expansion, the domestic CGM market is entering an accelerated penetration period driven by self-payment.

Mechanical thrombus removal ushered in a billion-dollar M&A at the beginning of 2026, and the M&A bets by giants have brought long-term value endorsement to this field.

From the clinical perspective, in the huge and complex vascular interventional system, mechanical thrombus removal has quickly stood out with advantages such as wide indication coverage, rapid vascular recanalization and shortened treatment time. It delivers the device directly to the thrombus site through a percutaneous interventional approach to remove the thrombus by mechanical means, which is particularly effective for patients with acute or subacute, central or mixed deep vein thrombosis. Compared with catheter-directed thrombolysis, it is more time-saving, uses fewer drugs and has a shorter hospital stay, and its advantages are more prominent in patients with low bleeding risk and long life expectancy.

Actions on the industrial side have pushed this track into the spotlight. The global market is led by Inari Medical and Penumbra, both of which have been acquired by giants at a high price.

Inari Medical was acquired by Stryker for 4.9 billion US dollars in 2025. After the completion of the acquisition, Inari contributed 590 million US dollars in revenue within 10 months, with a year-on-year growth of 52.3% in Q2 2025, becoming Stryker's fastest-growing business segment.

Penumbra takes the thrombus aspiration system as its core product and was acquired by Boston Scientific for 14.5 billion US dollars in 2026. The company expects its revenue growth rate in Q4 2025 to still reach 21.4%–22.0%, with an annual revenue of about 1.4 billion US dollars, a year-on-year increase of 17.3%–17.5%.

The domestic market also shows a strong momentum. The huge base of vascular disease patients combined with mature technology has enabled mechanical thrombus removal to maintain a high growth rate of over 20% in China, and a number of domestic products have been approved one after another. With more vascular interventional enterprises laying out synergistic product lines, the penetration rate is expected to further increase in the future.

Structural heart disease is the fastest-growing direction in the cardiovascular field in recent years, and transcatheter mitral and tricuspid valve therapy (TMTT) is one of the fastest-growing tracks in structural heart disease.

It is not accidental that TMTT has become one of the fastest-growing tracks in the medical device industry, but the aggregation of clinical value, industrial strength and future space.

From the perspective of clinical value, transcatheter mitral and tricuspid valve therapy is reshaping the pattern of cardiovascular treatment. Traditional open-heart surgery has high risks for elderly patients, while TMTT cuts in with a minimally invasive approach, which truly solves the most intractable valvular heart disease treatment gap in the aging era and promotes the structural migration of global treatment models.

From the perspective of industrial promotion, the performance of multinational leaders has given the most direct answer. Abbott's mitral and tricuspid valve business continues to climb, and Edwards Lifesciences' TMTT revenue in Q3 2025 reached 1.452 billion US dollars, a year-on-year surge of 59.3%, with PASCAL and EVOQUE becoming the twin engines driving growth. The continuous investment of enterprises and the rapid iteration of products have made this track show a growth trend of parallel technological breakthroughs and commercialization acceleration.

The domestic market is also accelerating its catch-up: the number of approvals for TMTT has expanded from 3 in 2024 to 6 in 2025, and the leap on the supply side is igniting the potential on the demand side.

From the perspective of future prospects, the story of this market is far from reaching its climax. Global enterprises generally believe that the penetration rate of TMTT is still in the early stage, and the real growth cycle has just begun. In China, the superposition of a huge patient base and rapidly expanding innovative supply will endow this track with long-term explosive power.

Transbronchoscopic surgical robots emerged as one of the fastest-growing tracks in the medical device field in 2025, and this product ushered in large-scale commercial volume expansion in 2025.

Transbronchoscopic surgical robots solve the core pain points of early lung screening and diagnosis. By introducing robot navigation technology and remote control technology, transbronchoscopic surgical robots can realize preoperative 3D model reconstruction and trajectory planning of the bronchial tree, and the combination of virtual images and real-time image navigation during surgery. Surgeons remotely and real-timely control the end movement of the flexible bronchoscope by operating the controller, which can reach more than 90% of the lung segment range (including sixth and above segmental bronchi), and can perform real-time and accurate biopsy or ablation surgery, improving the diagnostic accuracy of pulmonary lesions and the effect of early treatment.

2025 is the year when transbronchoscopic robots truly enter the stage of large-scale volume expansion. Three major transbronchoscopic surgical robots have obtained FDA approval worldwide: Intuitive Surgical's single-arm Ion platform, Johnson & Johnson's dual-arm Monarch platform, and Noah Medical's Galaxy system.

For Intuitive Surgical's Ion platform, the installed capacity reached 905 units, the cumulative surgical volume reached 38,000 cases, and the surgical volume growth rate exceeded 50% in 2025. The high clinical growth rate of equipment utilization shows that bronchoscopic robots are in the stage of large-scale volume expansion. The market is no longer in the installed capacity verification period, but has entered the stage of large-scale growth driven by clinical demand.

In the domestic market, there is also good news for this market. The National Medical Insurance Administration officially issued the Guidelines for the Project Establishment of Medical Service Price Items in the Category of Surgical and Therapeutic Auxiliary Operations (Trial), providing a national standard for charging in this track. In the future, products that can complete both diagnostic and therapeutic operations are expected to win a larger market space.

Affected by market headwinds, the global medical beauty market faced growth pressure in 2025. However, some products still achieved rapid growth and won the battle against headwinds. The "Liquid Facelift" achieved rapid growth in the domestic market.

Poly-L-lactic acid (PLLA) for Liquid Facelift is regarded as a high-growth track in the medical device field in 2025, and the core reason is that its mechanism of "stimulating collagen regeneration" is in line with the preference of domestic medical beauty seekers for natural, long-lasting and low-risk anti-aging methods. As medical beauty consumption upgrades from "filling type" to "regenerative type", PLLA has quickly become one of the key projects laid out by institutions by virtue of its more long-term tissue improvement ability, and also promoted the expansion trend of regenerative medicine-based medical beauty products.

The domestic growth momentum mainly comes from three aspects: first, the acceptance of "light medical beauty anti-aging" on the consumer side continues to improve, with both high unit price and repurchase rate; second, the policy side has stricter supervision on compliant medical beauty devices, making PLLA products with clinical evidence and compliant qualifications more competitive; third, the continuous innovation of local enterprises in production technology, particle stability and injection experience has reduced the use threshold and accelerated the domestic substitution.

The current market pattern presents a situation of "imported brands leading and domestic brands catching up rapidly". International manufacturers occupy the high-end market by virtue of mature clinical data and brand awareness, while domestic enterprises rapidly expand their market share through cost performance and channel penetration. In the future, the PLLA track will develop towards product differentiation, indication expansion and combined treatment plans, and is expected to maintain a high growth rate from 2025 to 2027, becoming one of the most potential sub-categories in the medical beauty regeneration field.

A hit product has also emerged in the household medical device scenario: non-invasive ventilators. The rapid growth of non-invasive ventilators is related to the improvement of consumers' health awareness, the reshaping of the market pattern and the global layout of domestic enterprises.

In 2025, the non-invasive ventilator market continued its strong growth momentum, especially a significant rebound in the US market. A non-invasive ventilator is a type of mechanical ventilation device that continuously delivers positive pressure airflow to the user through the mouth and nose in a non-invasive manner for controlling or assisting breathing, mainly used for the treatment of obstructive sleep apnea-hypopnea syndrome.

The recall of ventilators by Philips has reshaped the global ventilator market pattern, and domestic enterprises have seized the opportunity by virtue of their global layout. ResMed's revenue in the first three quarters exceeded 800 million yuan, a year-on-year increase of 34.24%, and the net profit reached 180 million yuan, a year-on-year increase of 43.87%, of which the overseas revenue was 558 million yuan, a year-on-year increase of 52.96%. As an overseas pioneer in respiratory treatment products, Yuyue Medical's ventilators, masks and other categories have maintained rapid growth and made breakthroughs in key countries and regions.

Against the background of the improvement of consumers' health awareness, the non-invasive ventilator market is expected to flourish further. ResMed pointed out at the 2026 JPM Conference that the treatment penetration rate of obstructive sleep apnea-hypopnea syndrome (OSA) is still low, with the penetration rate in the US market less than 20% and even lower than 10% in other regions of the world. Factors driving market expansion include the improvement of consumers' health awareness, the widespread use of GLP-1 drugs driving attention to sleep apnea, the continuous monitoring of sleep quality by wearable devices, and the increasing pressure on the medical system prompting payers and service providers to pay more attention to preventive treatment.

Another billion-dollar large single product has emerged in the vascular interventional field: the Shockwave IVL shockwave balloon, which has become Johnson & Johnson's 13th medical device product with sales exceeding 1 billion US dollars.

The core clinical value of IVL's breakthrough to the 1 billion US dollar scale and high growth lies in solving the calcification problem. IVL accurately acts on the calcified lesions under the coronary intima and media through acoustic pressure waves, effectively loosening or cracking the calcified tissue without damaging the vascular intima structure, restoring vascular compliance, thus creating more ideal operating conditions for subsequent stent implantation.

According to Johnson & Johnson's disclosure, the penetration rate of IVL in US coronary interventional therapy is about 10%. In addition to Johnson & Johnson, enterprises such as Boston Scientific and Abbott are also actively laying out this field. Considering that about 30% of patients with coronary atherosclerosis have calcified lesions, IVL still has a significant room for penetration improvement on the clinical side. With the launch of more products, the market is expected to further expand.

It is not difficult to find from the above sorted major fields that innovative products have brought new prosperity opportunities to medical devices and driven the rapid growth of the market. The ability to prospectively lay out high-growth fields and how to continue to innovate after the launch of innovative products have become the key points of competition. In the domestic market, innovation competition is generally more fierce, and enterprises need to experience brutal competition and win market share before they can usher in steady growth.